A large-scale Phase III study, SOLO1, further demonstrated that among 196 patients with BRCA1/2 mutations and platinum-sensitive recurrent ovarian cancer, Olaparib treatment resulted in a PFS of 19.1 months, compared to just 5.5 months in the placebo group. Here, BRCA1 is linked to ovarian carcinoma.